medigraphic.com

2000, Number 5

<< Back Next >>

Enf Infec Microbiol 2000; 20 (5)

Susceptibility of 1,100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries

Jacobs MR, Appelbaum PC

Language: Spanish
References: 28
Page: 198-205
PDF size: 57.73 Kb.


ABSTRACT

The antimicrobial susceptibility to β-lactam and non-β-lactam agents of 1,100 isolates of Streptococcus pneumoniae recovered in 1997 from 16 centers in Argentina, Brazil, Chile, Mexico, Panama, Venezuela and West Indies was studied using E-test and disk diffusion methods. A total of 23.6% of isolates had raised penicillin MICs (16.7%, intermediate and 6.9% resistant). The susceptibility of the other agents tested, from most active to least active, were amoxycillin/clavulanate (99.5% susceptible); chloramphenicol (93.2%); cefotaxime (91.7%); erythromycin (87.1%); tetracycline (74.6%); trimethoprim/sulphamethoxazole (TMP-SMZ) (55.4%); and cefaclor (52.8%). The highest proportion of strains resistant to penicillin, chloramphenicol, erythromycin, tetracyc1ine and TMP-SMZ was found in strains from Mexico while resistance to these agents was lowest in strains from the West Indies. Prevalence of penicillin resistance (including intermediate and resistant isolates) in each of the countries, from highest to lowest was, Mexico (40.8%); Chile (31.3%); Panama (23.0%); Venezuela (21.9%); Argentina (19.1%); Brazil (12.9%); and West Indies (7.1%). Based on current levels of antimicrobial resistance of S. pneumoniae in Latin American and Caribbean countries, continued surveillance efforts are necessary in order to guide clinical empiric treatment and provide for judicious use of antimicrobial agents. C 2000 Elsevier Science B. V. and International Society of Chemotherapy. All rights reserved.


REFERENCES

  1. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Clin Infect Dis 1992;14:801-7.

  2. DiFabio JL, Homma A, DeQuadros C. Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. Microb Drug Resistance 1997;3:131-3.

  3. Bolan G, Broome CV, Facklam RR et al. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986;104:1-6.

  4. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.

  5. Juliet C, Giglio MS, Camponovo R. Sensibilidad de Streptococcus pneumoniae y su importancia clínica. Rev Med Chil 1987;115:852-7.

  6. Rossi A, Ruvinsky R, Regueira M et al. Distribution of capsular types and penicillin-resistance of strains of Streptococcus pneumoniae causing systemic infections in Argentinean children under 5 years of age. Microb Drug Resistance 1997;3:135-l40.

  7. De Cunto Brandileone MC, Simonsen Dies Vieira V, Tadeu Casagrande S et al. Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Microb Drug Resistance 1997;3:141-6.

  8. Castaneda E, Leal AL, Castillo O et al. Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Microb Drug Resistance 1997;3:147-51.

  9. Echaniz-Aviles G, Velázquez-Meza MA, Carnalla-Barajas MN et al. Antimicrob susceptibilities and capsular types of invasive Streptococcus pneumoniae isolated in children in Mexico city. Microb Drug Resistance 1997;3:153-7.

  10. Hortal M, Pneumococcus Study Group. Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae clinical strains isolated from Uruguayan children with systemic infections. Microb Drug Resistance 1997;3:159-63.

  11. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. 6th ed; Approved Standard. [M2-A6] Wayne PA: National Committee for Clinical Laboratory Standards, 1997.

  12. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Testing, Eighth Informational Supplement. [M100-S8] Wayne PA: National Committee for Clinical Laboratory Standards, 1998.

  13. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.

  14. Jacobs MR, Bajaksouzian S, Zilles A et al. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to oral antimicrobial agents based on pharmacodynamic parameters: U.S. surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.

  15. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: results from the SENTRY antimicrobial surveillance program. Clin Infect Dis 1997;27:764-70.

  16. Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR. Craig W, Yagupsky P. Bacteriologic efficacious of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43-50.

  17. Dagan R, Johnson CE, McLinn S, Abughali N, Feris J, Leibovits E et al. Bacteriologic and clinical efficacy of amoxycillin/clavulanate versus azithromycin in acute otitis media Pediatr Infect Dis J 2000;19:95-104.

  18. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing. [M100-S10] Wayne PA: National Committee for Clinical Laboratory Standards, 2000.

  19. Mogdasy MC, Camou T, Fajardo C, Hortal M. Colonizing and invasive strains of S. pneumoniae in Uruguayan children: type distribution and patterns of antibiotic resistance. Pediatr Infect Dis J 1992;11:648-l52.

  20. Dowell SF, Whitney CG, Schwartz B. Regional characteristics of drug-resistance respiratory pathogens. Am J Med Continuing Educ Ser 1997;2:9-16.

  21. Zenni MK, Cheatham SH, Thompson JM et al Streptococcus pneumoniae colonization in the young child: association with otitis media and resistance to penicillin. J Pediatr 1995;127:533-7.

  22. Nava JM, Bella F, Garau J et al. Predictive factors for Invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population based study. Clin Infect Dis 1994;19:884-l90.

  23. Reichler MR, Allphin AA, Breiman RF et al. The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio, J Infect Dis 1992;166:1346-l53.

  24. Dowell SF, Butler JC, Giebink GS et al. Acute otitis media; management and surveillance in an era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group (DRSPTWG). Pediatr Infect Dis J 1999;18:1-9.

  25. McCracken GH, Nelson JD, Kaplan SL et al. Consensus report; antimicrobial therapy for bacterial meningitis in infants and children. Pediatir Infect Dis J 1987;6:501-5.

  26. McCracken GH, Sakata Y. Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae with different susceptibilities to penicillin. Antimicrob Agents Chemother 1985;27:141-5.

  27. Lopes E. Meropenem Study Group, Meropenem versus cefotaxime or ceftriaxone for bacterial meningitis [abstract 638]. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:236.

  28. Pallares R, Gudiol F, Linares J et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumoniae caused by penicillin-resistant pneumococci. N Engl J Med 1987;317:18-22.




2020     |     www.medigraphic.com